Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) (PREVICHARM)
Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)
Sponsor: Carlos III Health Institute
This PHASE2/PHASE3 trial investigates Coronavirus Infection and Hydroxychloroquine and is currently ongoing. Carlos III Health Institute leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
▶ Show 1 earlier version
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Carlos III Health Institute
- Instituto de Investigacion Biomedica de Malaga
- University of Malaga
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.